Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GILT: Oral Vinorelbine Consolidation in Stage III NSCLC
NCT00683514Phase 3Completed
- Sponsor
- Pierre Fabre Laboratories
- Start
- Apr 2005
- Primary completion
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of vinorelbine in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Pierre Fabre Laboratories. Primary endpoint: Progression-Free Survival. Started Apr 2005; status: completed.
02
Drugs
vinorelbine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00683514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00683514.